Sector intelligence and perspective
June 18, 2018
After four (4) positive closes, a downside positioned market, decreasing advance/decline lines, low volumes and downside riding ETFs sets the stage for …
A depreciating basket of sector stocks?
As the IBB (-0.72%), XBI (-0.57%), XLV (-0.54) and IWM (-0.64%) are dropping
If you were a subscriber, you’d understand how today’s pre-open indications shed light on share pricing! Read them here or spend an hour looking it all up !
There is no breadline for share pricing and fact based intelligence!
June 18, 2018
For continued access to what one industry CEO calls the “Bible” for smart investing in the RegMed, gene and cell therapy sector, click on the button below:
http://www.regmedinvestors.com/create-account
Why spend time searching for sector news and analytics … it’s all right here!
Review daily indicators – pre-open and close, trends – whether they’re your friend or not, advance/decline lines of 45 covered companies, volatility responses followed by the factors involving decliners versus gainers and their daily percentages.
I “never leave an investor uninformed”
June 18, 2018
Even as the session reduced losses with low volume to the upside and higher volume to the downside
Gene editing stocks - CRSP (+$3.32), EDIT (+$1.73) and NTLA (+$1.56) are headed into SELL zone
Out and about: Stories of the day – SLDB jumps, BSTG is up on what (?) and VSTM is up and stutters as ATHX gets no respect
Of the 45 covered the 22 downside equities finished in a range of -$0.01 to -$2.15 with biggest bottoms of -$6.45 and $3.70 and $2.97 while the 20 upside equities oscillated from +$0.01 to $2.88 with a topper of $3.32 and 3 flat closes
We keep you informed, if you want to make a return on investment (ROI) from the sector - be a subscriber!
There is no breadline for fact based intelligence!
June 18, 2018
VSTM’s shares up +$1.379 or +21.13% at the open - SELL on the dramtic incline
June 18, 2018
SLDB closed up +$1.81 on Friday and is up +$2.70 or +10.19% in the pre-market The clinical hold was imposed in March and came after the unexpected hospitalization of a patient in the P1/2 trial, called Ignite DMD.
June 7, 2018
MDXG is a moving downside of -$1.29 or approximately -15.35% to $6.92 After a previous close of $8.32 and an opening bid of $5.88 Interesting “stat”: In 2017, the average restatement covered 509 days, the lowest value since 2009, according to Audit Analytics. MDXG’s restatement will cover nearly 2,099 days or roughly four times the average <WSJ>.
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
© 2018 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
